1,1'-oxybis(but-3-en-2-ol) | 83682-67-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,1'-oxybis(but-3-en-2-ol)
• 英文别名: 1,1'-Oxybis-3-buten-2-OL；1-(2-hydroxybut-3-enoxy)but-3-en-2-ol
• CAS: 83682-67-1
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: SKIOXONYFXKRIC-UHFFFAOYSA-N

物化性质

• 沸点：
  262.1±40.0 °C(Predicted)
• 密度：
  1.034±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,1'-oxybis(but-3-en-2-ol) 在 bis(1,5-cyclooctadiene)diiridium(I) dichloride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 34.0h， 生成 、
  参考文献：
  名称：

  An Efficient Synthesis of Bridged Heterocycles from an Ir(I) Bis-Amination/Ring-Closing Metathesis Sequence

  摘要：

  The amination of bis-allylic imidates using an Iridium(I) catalyst leads to the efficient formation of 2,6-divinyl heterocycles. Careful screening of amines, solvents, and conditions has led to the discovery of a system that favors formation of the desired cis products with synthetically useful levels of diastereoselectivity, and these results are further explained by computer based transition state energy calculations. Exposure of the heterocycles to ring-closing metathesis catalysts leads to the desired bridged heterocyclic systems.

  DOI：

  10.1021/ol302108m
• 作为产物：
  描述：

  乙烯基溴化镁 、 anhydroerythritol 在 碘苯二乙酸 作用下， 以 二氯甲烷 、 乙醚 为溶剂， 反应 17.33h， 以79%的产率得到1,1'-oxybis(but-3-en-2-ol)
  参考文献：
  名称：

  An Efficient Synthesis of Bridged Heterocycles from an Ir(I) Bis-Amination/Ring-Closing Metathesis Sequence

  摘要：

  The amination of bis-allylic imidates using an Iridium(I) catalyst leads to the efficient formation of 2,6-divinyl heterocycles. Careful screening of amines, solvents, and conditions has led to the discovery of a system that favors formation of the desired cis products with synthetically useful levels of diastereoselectivity, and these results are further explained by computer based transition state energy calculations. Exposure of the heterocycles to ring-closing metathesis catalysts leads to the desired bridged heterocyclic systems.

  DOI：

  10.1021/ol302108m

文献信息

• [EN] COMPOSITIONS COMPRISING AN HIV PROTEASE INHIBITOR<br/>[FR] COMPOSITIONS COMPORTANT UN INHIBITEUR DE LA PROTEASE DU VIH
  申请人：PFIZER

  公开号：WO2005056542A1

  公开（公告）日：2005-06-23

  The present invention relates to pharmaceutical compositions comprising amorphous (4R)-N-allyl-3-(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, their methods of preparation, their use in inhibiting the HIV protease enzyme, and their use in the manufacture of a medicament for the treatment HIV-infected mammals, such as humans.

  本发明涉及包含非晶态(4R)-N-烯丙基-3-(2S,3S)-2-羟基-3-[(3-羟基-2-甲基苯甲酰)氨基]-4-苯基丁酰}-5,5-二甲基-1,3-噻唑烷-4-羧酰胺，或其药学上可接受的盐或溶剂的制药组合物，其制备方法，其在抑制HIV蛋白酶酶的用途，以及其在制造用于治疗HIV感染哺乳动物，如人类的药物中的用途。
• Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
  申请人：XenoPort, Inc.

  公开号：US20140056973A1

  公开（公告）日：2014-02-27

  Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.

  口服剂型和颗粒制剂中含有高含量的甲基氢富马酸前药。
• Compositions comprising an HIV protease inhibitor
  申请人：Smith Wendell Scott

  公开号：US20050129772A1

  公开（公告）日：2005-06-16

  The present invention relates to pharmaceutical compositions comprising amorphous (4R)—N-allyl-3-(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, their methods of preparation, their use in inhibiting the HIV protease enzyme, and their use in treating HIV-infected mammals, such as humans.

  本发明涉及制药组合物，包括非晶态(4R)-N-烯丙基-3-(2S,3S)-2-羟基-3-[(3-羟基-2-甲基苯甲酰)氨基]-4-苯基丁酰}-5,5-二甲基-1,3-噻唑烷-4-羧酰胺或其药学上可接受的盐或溶剂，它们的制备方法，它们在抑制HIV蛋白酶酶中的使用以及它们在治疗HIV感染的哺乳动物，例如人类中的使用。
• Polymerization process
  申请人：MONSANTO COMPANY

  公开号：EP0067625A2

  公开（公告）日：1982-12-22

  A process is described in which polymerization of a free-radical polymerizable monomer is initiated using as initiator a prepolymerizate obtained by oxidative polymerization of a compound having at least two unsaturations that are each a, β or β, y to nucleophilic groups activating the unsaturation towards oxidative polymerization. The initiators are stable but reactive and actually enter into the polymerization reaction, permitting the product to be tailored to the desired end use. They can work in the presence of oxygen if desired.

  描述了一种工艺，其中使用一种预聚物作为引发剂，引发可自由基聚合的单体的聚合反应，这种预聚物是通过对一种化合物进行氧化聚合而得到的，该化合物具有至少两个不饱和基团，每个不饱和基团都是 a、β 或 β、y，这些亲核基团激活了不饱和基团，使其发生氧化聚合。 引发剂是稳定的，但具有活性，可实际进入聚合反应，从而使产品适合所需的最终用途。 如果需要，它们可以在有氧气的情况下工作。
• Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
  申请人：Pfizer Products Inc.

  公开号：EP1961419A1

  公开（公告）日：2008-08-27

  The present invention relates to a unitary dosage form comprising: (a) a solid amorphous dispersion comprising a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer; and (b) an HMG-CoA reductase inhibitor; wherein said concentration-enhancing polymer is a neutralized acidic polymer in which at least 90% of the acidic moieties have been neutralized.

  本发明涉及一种单一剂型，包括：(a) 由胆固醇酯转移蛋白抑制剂和浓度增强聚合物组成的固体无定形分散体；以及 (b) HMG-CoA 还原酶抑制剂；其中所述浓度增强聚合物是一种中和酸性聚合物，其中至少 90% 的酸性分子已被中和。